Cipla receives final approval for the generic version of Somatuline Depot Injection
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated